Day: March 14, 2024

MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat systemic and neurological autoimmune diseases, progressing toward expected IND submission in Q2 2024 and initiation of Phase 1 SAD/MAD study midyear MRT-8102 nominated as first development candidate for NEK7 program, targeting diseases driven by IL-1b and the NLRP3 inflammasome; IND submission expected in Q1 2025 Entered into strategic discovery collaboration with Roche, further expanding potential applications of QuEEN™ discovery engine Strong cash position expected to fund operations into H1 2026 and enable advancement of MRT-2359, MRT-6160, and MRT-8102 programs through...

ThinAir® Ka2517 antenna to be certified for Telesat Lightspeed™ network HAWTHORNE, Calif. and OTTAWA, March 14, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, and ThinKom Solutions, Inc., a leading designer and manufacturer of high performance satcom antennas, today announced an expanded development partnership to certify ThinKom’s ThinAir Ka2517 antenna for the Telesat Lightspeed Low Earth Orbit (LEO) satellite network. The multi-year agreement calls for the organizations to cooperate on the integration and certification of the Ka2517 antenna with an airborne modem to enable communications across the Telesat Lightspeed Ka-band LEO network. “ThinKom is keen to extend its position as the proven leader in airborne, multi-constellation, multi-orbit...

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 continues to provide runway into the second half of 2026 CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2023. The company also announced that Chief...

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2 ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designation ACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partner Cash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026Lausanne, Switzerland, March 14, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention...

Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the active ingredient (i.e., “Drug Substance”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots. Sequel is a U.S. based specialty pharma company with expertise in developing and commercializing niche drugs. It has committed to provide all funding needed to return Kinlytic to global markets, initially for the US$...

Speakers and Sponsors Include Executives from Brands Such as Netflix, Samsung, and Hasbro LOS ANGELES, March 14, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company in North America, today announced that its next live event Pocket Gamer Connects (PGC) will take place in San Francisco on March 18-19. Being held immediately prior to the Game Developers Conference (GDC 2024), PGC San Francisco is expected to draw a large crowd of video game developers, publishers and other industry professionals to connect, do business and learn from industry leaders. In partnership with Game Connection America, a renowned producer and promoter of international games industry events for over 23 years, PGC San Francisco will feature talks, panels, and round-tables...

ROAD TOWN, British Virgin Islands, March 14, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA32) (OTCQX: ORAAF) (“Aura Minerals” or the “Company”) announces today that the Toronto Stock Exchange (the “TSX”) has accepted the Company’s notice of intention to launch a normal course issuer bid (the “NCIB”) for its issued and outstanding common shares (the “Common Shares”) listed on the TSX. The Company is also announcing the concurrent launch of a buyback program (the “BDR Buyback Program”) for its Brazilian depositary receipts (the “BDRs”) which are listed on the B3 S.A. – Brasil, Bolsa, Balcão (the “B3”), for the purchase of BDRs by the Company, its subsidiaries or investment vehicles. Rodrigo Barbosa, Aura Minerals’ President,...

– IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile – – 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity – – Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg – – Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity – – Phase 2a portion of the study underway with three monotherapy and two combination arms in earlier lines of treatment, with initial data from multiple arms expected in 2024...

43% increase in net revenue reaching $7.1 million in Q1 2024, up from $5.0 million in Q1 2023, marking the Company’s fourth consecutive quarter of revenue growth. 87% increase in US sales to $1.4 million, fueled by Black Friday Cyber Monday success and the new punch lineup sold through Amazon, where GURU stands out as the #1 Organic Energy Drink1. 35% increase in Canadian sales to $5.7 million, with increased sales velocities in urban areas. Gross profit of $3.8 million, compared to $2.7 million in Q1 2023. Robust gross margin of 52.9% in Q1 2024. Net loss decreased to $1.9 million, compared to $2.6 million in Q1 2023, continuing to focus on reducing loss to return to profitability in the coming years. Robust financial position with $41.2 million in cash, cash equivalents and short-term investments, and unused credit facilities,...

CANTANHEDE, Portugal, March 14, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced a groundbreaking achievement in the medical cannabis industry in Portugal. Following the successful approval of our Tilray whole flower THC 18, Tilray Medical has now received approval for the first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20, in Portugal, marking a significant milestone in medical cannabis availability and patient care within the country. Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said: “This is a monumental step forward for patient care in Portugal. With the...